The industry has been rocked with the announcement of another pharmaceutical mega-merger, as it emerged that AbbVie had sealed an agreement with Allergan to acquire the latter for approximately $63 billion, making it one of the biggest mergers of its kind.
The total valuation of the deal is based on the closing price on 24 June of AbbVie’s common stock of $78.45, and will take the form of a cash and stock transaction.
